ReproCELL Q1 Revenue Rises 14.9% as R&D Push Widens Operating Loss to ¥310 Million

Revenue grew 14.9%, but spending grew faster

ReproCELL Incorporated (TSE: 4978), which sells research reagents, cells and contract services built on induced pluripotent stem (iPS) cell technology and is developing regenerative-medicine products, published consolidated results for the first quarter of the fiscal year ending March 2027 — the three months from April 1 to June 30, 2026 — on August 13, 2026 under Japanese GAAP. Revenue rose 14.9% to ¥546 million. The operating loss was ¥310 million against ¥291 million a year earlier, while the ordinary loss narrowed to ¥149 million from ¥301 million and the loss attributable to owners of the parent to ¥149 million from ¥304 million, a loss per share of ¥1.56 against ¥3.21. The company's shares are listed on the Tokyo Stock Exchange.

The top line moved in two directions. Product sales rose 29.3% to ¥366.0 million, while service revenue fell 6.2% to ¥180.7 million. Cost of sales grew only 7.2% to ¥301.6 million, so gross profit rose 26.0% to ¥245 million and the gross margin widened from 40.9% to 44.8%. That was not enough to cover the expense line. Selling, general and administrative expenses rose 14.5% to ¥556 million, an increase of ¥70.5 million against a gross-profit gain of ¥50.6 million, and most of the increase was research: R&D expenses climbed 27.8% to ¥207 million, up ¥45.2 million, while other SG&A rose 7.8% to ¥348.5 million. The operating loss therefore widened by ¥19.9 million.

Subsidies and currency, not trading, halved the net loss

The improvement below the operating line came from non-operating income, which rose to ¥162.8 million from ¥17.3 million. It comprised ¥89.7 million of subsidy income, which did not appear a year earlier, a foreign-exchange gain of ¥47.5 million against an exchange loss of ¥4.1 million, and interest income of ¥25.4 million against ¥16.9 million. The filing does not say what the subsidy relates to. Non-operating expenses fell to ¥0.8 million from ¥28.1 million, chiefly because last year's ¥23.5 million equity-method investment loss did not recur. There were no extraordinary items, and income taxes were ¥0.5 million, so the ordinary loss of ¥149 million passed almost unchanged to the bottom line. The comprehensive loss was ¥150 million against ¥325 million.

Research Support turned a profit; Medical is still in the red

Research Support, which supplies universities, public research institutes and pharmaceutical companies with research reagents, cells, iPS-cell generation and other contract services and distributes third-party laboratory instruments, generated revenue of ¥483 million, up 10.3%, and a segment profit of ¥20 million against a loss of ¥26 million. By customer location, the segment's sales in the United States rose to ¥250.1 million from ¥210.4 million, in Japan to ¥66.8 million from ¥55.2 million and in India to ¥23.8 million from ¥15.5 million, while sales in the United Kingdom fell to ¥142.8 million from ¥157.4 million. The filing does not attribute the growth to particular products.

Medical — regenerative-medicine product development, contract manufacturing of iPS-cell products and clinical-testing services — grew revenue 69.2% to ¥63 million, all of it in Japan, and narrowed its segment loss to ¥13 million from ¥58 million. Unallocated corporate costs, mainly general administration, fell to ¥156 million from ¥217 million. Segment results are reconciled to ordinary loss: the two segments together earned ¥7 million, and the corporate costs took the total to the ordinary loss of ¥149 million.

Approval filing for Stemchymal

On June 24, 2026 the company filed in Japan for manufacturing and marketing approval of Stemchymal, an adipose-derived mesenchymal stem-cell product developed by Steminent Biotherapeutics Inc. of Taiwan, for suppressing the progression of ataxia in spinocerebellar degeneration (types SCA3 and SCA6). ReproCELL holds an exclusive commercial license for that indication in Japan. The product is designated for priority review, which targets a decision within nine months of the application being accepted; after approval Steminent is to manufacture it and ReproCELL to sell and ship it in Japan. On June 18 the company applied to Kanagawa Prefecture for the marketing license it needs to act as the product's marketing authorization holder. Elsewhere in the pipeline, the filing says it is preparing clinical trials of iPS-derived neural glial cells in amyotrophic lateral sclerosis (ALS) and of a GPC-1 CAR-T therapy in esophageal cancer, alongside work on tumor-infiltrating lymphocyte (TIL) therapy.

Balance sheet: new equity in, cash shifted into investment securities

Total assets were ¥9,800 million at June 30, 2026 against ¥9,652 million at March 31. Current assets fell by ¥810 million to ¥6,518 million, mainly because cash and deposits declined by ¥608 million to ¥1,995 million and current securities by ¥284 million to ¥3,619 million, while non-current assets rose by ¥958 million to ¥3,281 million on an increase of ¥980 million in investment securities, to ¥2,894 million. Liabilities were ¥727 million. Net assets rose by ¥225 million to ¥9,072 million and the equity ratio stood at 92.5% against 91.7%.

The rise in net assets came from a third-party allotment of new shares to CVI Investments, Inc., paid in on June 11, 2026, which added ¥186 million each to share capital and capital surplus; shares issued rose from 95,147,891 to 98,079,891. The quarter's loss widened the accumulated deficit by ¥149 million. The company did not prepare a quarterly cash-flow statement; depreciation was ¥20.2 million against ¥15.9 million.

A second equity tranche, a going-concern disclosure and unchanged guidance

After the quarter, the board resolved on July 1, 2026 to make the second issuance under an equity program agreed with CVI Investments, Inc., a fund managed by Heights Capital Management, Inc.: 2,932,000 new shares at ¥112, for ¥328,384,000, with a payment date of July 16, 2026, together with 29,320 stock acquisition rights (the 18th series, 100 shares each) issued at ¥113 per right with an exercise price of ¥149, exercisable from July 17, 2026 to July 16, 2030. The planned uses of the combined proceeds are ¥300 million for trial and approval-filing costs of the TIL therapy project, ¥295 million for research and trial preparation of the GPC-1 CAR-T therapy and ¥165 million for working capital, ¥760 million in all.

The filing also discloses that, because research, development and trial costs for iPS-cell and regenerative-medicine products run ahead of revenue and operating losses have continued, events or conditions exist that may cast significant doubt on the company's ability to continue as a going concern. It states in the same passage that its financial base is stable, citing cash and deposits of ¥1,995 million and short-term securities of ¥3,619 million, and that it is aiming to reach profitability as early as possible; the quarterly financial statements themselves carry no going-concern note.

Full-year guidance, published on May 14, 2026, was left unchanged: revenue of ¥2,629 million, up 17.7%, an operating loss of ¥630 million, ordinary and net losses of ¥458 million each, and a loss per share of ¥4.68, which reflects the June allotment. First-quarter revenue represents 20.8% of the full-year target. The company paid no dividend for the fiscal year ended March 2026 and forecasts none for the current year.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.